Synonyms: compound 99 [PMID 25380412]
Compound class:
Synthetic organic
Comment: GLPG0974 was a lead clinical development candidate. It acts as an antagonist of the free fatty acid receptor 2 (FFA2) [3]. FFA2 is a GPCR involved in the mediation of inflammatory responses.
Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖ |
|
No information available. |
Summary of Clinical Use |
A Phase 2 clinical trial evaluating GLPG0974 in ulcerative colitis has been completed (NCT01829321). Safety, pharmacokinetics and pharmacodynamics of GLPG0974 in healthy subjects are reported in [2]. However, despite mediating an inhibition of neutrophil influx, GLPG0974 failed to reach the study endpoint in ptients with ulcerative colitis. |